MAPK Pathway Drugs and Ocular Toxicity
MAPK stands for Mitogen-Activated Protein Kinase. The name reflects the pathway's original discovery as a kinase cascade activated by mitogens — extracellular signals (such as growth factors) that stimulate cell division (mitosis).
The MAPK Cascade
The MAPK/RAS-RAF-MEK-ERK cascade is a highly conserved, three-tiered signaling pathway that transmits extracellular signals from the cell surface to the nucleus, regulating cell proliferation, differentiation, survival, and migration.
Diagram of Pathway
Step-by-Step Signal Transduction
Extracellular stimulus → Receptor activation: Growth factors bind to receptor tyrosine kinases (RTKs) such as EGFR, triggering receptor dimerization and autophosphorylation.
Adaptor protein recruitment → RAS activation: Phosphorylated RTKs recruit adaptor proteins (Shc, Grb2) and the guanine nucleotide exchange factor SOS, which converts RAS from inactive (RAS-GDP) to active (RAS-GTP). Three RAS isoforms exist: HRAS, KRAS, and NRAS.
RAS → RAF (MAP3K tier): Active RAS-GTP recruits RAF kinases (ARAF, BRAF, CRAF) to the plasma membrane for activation. BRAF is the most potent activator and the most frequently mutated in cancer (V600E).
RAF → MEK (MAP2K tier): Activated RAF phosphorylates MEK1/2. MEK is the only known physiological substrate of RAF.
MEK → ERK (MAPK tier): Activated MEK1/2 phosphorylate ERK1/2 at the conserved TEY motif. Both phosphorylation events are required for full activation.
ERK → Downstream effectors: ERK1/2 phosphorylate over 250 known substrates in the cytoplasm and nucleus, activating transcription factors (Elk-1, c-Fos, c-Myc, AP-1) that drive cell cycle progression.
Key Regulatory Features
Signal amplification: Each tier amplifies the signal from upstream to downstream
Negative feedback: ERK phosphorylates upstream components (SOS, RAF) to attenuate signaling
Scaffold proteins (KSR1/2, IQGAP1, MP1) organize cascade components into signaling complexes
Crosstalk: Cross-communication with the PI3K/AKT pathway and other MAPK cascades (JNK, p38)
Relevance to Cancer and Ocular Toxicity
Oncogenic mutations — most commonly in KRAS (~30% of all cancers) and BRAF V600E (~7% of all cancers, ~60% of melanomas) — constitutively activate this cascade. Ocular toxicity from MAPK pathway inhibitors arises because ERK signaling is critical for retinal pigment epithelium (RPE) homeostasis; ERK loss in RPE cells leads to decreased RPE65 expression and retinal degeneration.
Drugs in the MAPK/RAS-RAF-MEK-ERK Pathway With Ocular Toxicity
BRAF Inhibitors (Type I)
| Drug (Brand Name) | Primary Ocular Toxicities | Key Details |
| Vemurafenib (Zelboraf) | Uveitis (anterior uveitis, panuveitis), photosensitivity | Uveitis in ~4% of patients; highest ocular signal among BRAF inhibitors |
| Dabrafenib (Tafinlar) | Uveitis | Lower incidence (~1%); favorable ocular profile in pediatric cohorts |
| Encorafenib (Braftovi) | Uveitis (when combined with binimetinib) | 4% uveitis incidence in COLUMBUS trial |
MEK Inhibitors
| Drug (Brand Name) | Primary Ocular Toxicities | Key Details |
| Trametinib (Mekinist) | RPED, serous retinal detachment, chorioretinopathy, RVO | FDA label warns of RPED and RVO |
| Cobimetinib (Cotellic) | Serous retinopathy (MEKAR), blurred vision | 17.9% serous retinopathy in integrated analysis; median onset 15 days |
| Binimetinib (Mektovi) | Serous retinopathy, RVO, uveitis | FDA label mandates visual symptom assessment at each visit |
| Selumetinib (Koselugo) | MEKAR, blurred vision | FDA-approved for pediatric [NF1](https://www.openevidence.com/rare-disease/neurofibromatosis-type-1); ~1.4% central serous retinopathy |
Pan-RAF Inhibitors
| Drug (Brand Name) | Primary Ocular Toxicities | Key Details |
| Tovorafenib (Ojemda) | MEKAR, photosensitivity, periorbital edema | Pan-RAF inhibitor; ocular profile overlaps with MEK inhibitors |
| Naporafenib (investigational) | Expected class-related retinopathy | Being studied in combination with trametinib |
| Sorafenib (Nexavar) | Blurred vision, conjunctivitis | First-generation pan-RAF inhibitor; less retinal toxicity than MEK inhibitors |
| CH5126766/VS-6766 (investigational, dual RAF-MEK) | RPED (30%), blurred vision/color changes (49%) | Very high ocular toxicity rate due to potent MAPK suppression |
Eye Diseases Associated With Tovorafenib
Tovorafenib (Ojemda), a pan-RAF kinase inhibitor approved for pediatric [low-grade glioma](https://www.openevidence.com/rare-disease/low-grade-astrocytoma), is associated with several ocular adverse events:
These effects are considered a class effect of MAPK pathway inhibition, particularly due to downstream suppression of ERK signaling in the retinal pigment epithelium.
ERK Inhibitors
| Drug (Brand Name) | Primary Ocular Toxicities | Key Details |
| Ulixertinib/BVD-523 (investigational) | Subretinal fluid (MEKAR-like), intraretinal edema | 100% bilateral, 95% foveal involvement; all cases reversible |
| ATG-017 (investigational) | Retinopathy (grade 3 DLT), blurred vision | Dose-limiting ocular toxicity at higher doses |
| LY3214996 (investigational) | Expected class-related retinopathy | Preclinical data show ERK loss in RPE leads to retinal degeneration |
KRAS Inhibitors
| Drug (Brand Name) | Primary Ocular Toxicities | Key Details |
| Sotorasib (Lumakras) | Conjunctivitis (11% in mCRC combination arm) | Minimal retinal toxicity; no MEKAR-type events |
| Adagrasib (Krazati) | No significant ocular toxicity reported | Primary toxicities are GI and hepatic |
Key Patterns by Pathway Target
MEK inhibitors carry the highest ocular risk (MEKAR, serous retinopathy, RVO), occurring in up to 90% of patients on subclinical OCT
BRAF inhibitors predominantly cause uveitis rather than retinopathy
ERK inhibitors produce MEKAR-like retinopathy with additional intraretinal edema, but events appear self-limited
KRAS inhibitors have minimal ocular toxicity
References
Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK Pathway in Cancer Evolution and Treatment.
Semin Cancer Biol. 2022;85:123-154.
PMID: 33992782 Barbosa R, Acevedo LA, Marmorstein R. The MEK/ERK Network as a Therapeutic Target in Human Cancer.
Mol Cancer Res. 2021;19(3):361-374.
PMID: 33139506 Roberts PJ, Der CJ. Targeting the Raf-Mek-Erk Mitogen-Activated Protein Kinase Cascade for the Treatment of Cancer.
Oncogene. 2007;26(22):3291-3310.
PMID: 17496923 Roskoski R. ERK1/2 MAP Kinases: Structure, Function, and Regulation.
Pharmacol Res. 2012;66(2):105-143.
PMID: 22569528 Food and Drug Administration. MEKTOVI (binimetinib) prescribing information. 2025.
FDA Label*
Food and Drug Administration. Mekinist (trametinib) prescribing information. 2026.
FDA Label*
Food and Drug Administration. LUMAKRAS (sotorasib) prescribing information. 2025.
FDA Label*
Mettler C, Monnet D, Kramkimel N, et al. Ocular Safety Profile of BRAF and MEK Inhibitors: Data From the World Health Organization Pharmacovigilance Database.
Ophthalmology. 2021;128(12):1748-1757.
PMID: 34000304 Huang S, Guo Z, Wang M, et al. Ocular Adverse Events Associated With BRAF and MEK Inhibitor Combination Therapy: A Pharmacovigilance Disproportionality Analysis of the FDA Adverse Event Reporting System.
Expert Opin Drug Saf. 2023.
PMID: 36896641 Zhang Z, Wu Q, Wang Y, et al. Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Pharmacoepidemiol Drug Saf. 2025.
Barteselli G, Goodman GR, Patel Y, et al. Characterization of Serous Retinopathy Associated With Cobimetinib: Integrated Safety Analysis of Four Studies.
Drug Saf. 2022;45(12):1541-1555.
PMID: 36310331 Guo C, Chénard-Poirier M, Roda D, et al. Intermittent Schedules of the Oral RAF-MEK Inhibitor CH5126766/VS-6766 in Patients With RAS/RAF-mutant Solid Tumours and Multiple Myeloma: A Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study.
Lancet Oncol. 2020;21(11):1478-1488.
DOI Francis JH, Canestraro J, Haggag-Lindgren D, et al. Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
Ophthalmol Retina. 2021;5(12):1200-1215.
PMID: 34102344 Sullivan RJ, Infante JR, Janku F, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients With MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Cancer Discov. 2018;8(2):184-195.
PMID: 29247021 Wahlroos S, Teng C, Tran B, et al. Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors. 2024 ASCO Annual Meeting.
ClinicalTrials.gov: NCT04305249 Sammons RM, Ghose R, Tsai KY, Dalby KN. Targeting ERK beyond the boundaries of the kinase active site in melanoma.
Mol Carcinog. 2019;58(9):1551-1570.
PMID: 31148235 Shang J, Lu S, Jiang Y, Zhang J. Allosteric modulators of MEK1: drug design and discovery. Chem Biol Drug Des. 2016.
Huang S, Zhang Y, Shu H, et al. Advances of the MAPK pathway in the treatment of spinal cord injury. CNS Neurosci Ther. 2024.
Fang JY, Richardson BC. The MAPK Signalling Pathways and Colorectal Cancer. Lancet Oncol. 2005.
Terrell EM, Morrison DK. Ras-Mediated Activation of the Raf Family Kinases. Cold Spring Harb Perspect Med. 2019.
Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 2011.
Pyakurel A, Balmer D, Saba-El-Leil MK, et al. Loss of Extracellular Signal-Regulated Kinase 1/2 in the Retinal Pigment Epithelium Leads to RPE65 Decrease and Retinal Degeneration. Mol Cell Biol. 2017.